Sugi Predict

Sugi Predict / Targets / LTB4R2

LTB4R2

Leukotriene B4 receptor 2 · Q9NPC1 · LTB4R2 on Sugi Atlas →

46,519 patent compounds predicted against LTB4R2, 25,274 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2394 SCHEMBL2394 0.75 20/20
SCHEMBL2395 SCHEMBL2395 0.75 20/20
SCHEMBL2785 SCHEMBL2785 0.63 20/20
SCHEMBL2786 SCHEMBL2786 0.63 20/20
SCHEMBL3417 SCHEMBL3417 0.70 19/20
SCHEMBL2097 SCHEMBL2097 0.65 19/20
SCHEMBL2872 SCHEMBL2872 0.65 19/20
SCHEMBL2364 SCHEMBL2364 0.80 18/20
SCHEMBL2365 SCHEMBL2365 0.80 18/20
SCHEMBL2089 SCHEMBL2089 0.55 17/20
SCHEMBL2225 SCHEMBL2225 0.54 17/20
SCHEMBL2445 SCHEMBL2445 0.53 17/20
SCHEMBL2730 SCHEMBL2730 0.53 17/20
SCHEMBL2305 SCHEMBL2305 0.50 17/20
SCHEMBL2043 SCHEMBL2043 0.55 16/20
SCHEMBL2124 SCHEMBL2124 0.54 16/20
SCHEMBL1986 SCHEMBL1986 0.53 16/20
SCHEMBL2454 SCHEMBL2454 0.53 15/20
SCHEMBL1900 SCHEMBL1900 0.53 14/20
SCHEMBL202160 SCHEMBL202160 0.61 13/20

Clinical trials — most relevant to LTB4R2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Open-label Study of the Effects of Montelukast in Patients With Chronic Cough PHASE4COMPLETED
Predicting Response to Standardized Pediatric Colitis Therapy PHASE4COMPLETED
TEAM (Trial on Efficacy and Quality of Life Among Asthmatic Patient With Montelukast) PHASE4COMPLETED
Exercise Induced Bronchospasm in Children PHASE4COMPLETED
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite PHASE2/PHASE3WITHDRAWN
Montelukast in Parkinson Disease PHASE2/PHASE3RECRUITING
Aspirin for Uncontrolled Asthma PHASE3COMPLETED
Montelukast for Early Life Wheezing PHASE2/PHASE3COMPLETED
Serum Intercellular Adhesion Molecule -1 in Acne Vulgaris Patients : Effect of Montelukast PHASE3UNKNOWN
Predicting the Response to Montelukast by Genetic Variation in Asthmatics PHASE3COMPLETED
Wheeze and Intermittent Treatment PHASE3COMPLETED
GSK2190915 Neutrophilic Asthma Study PHASE2COMPLETED
Treatment of Bronchial Asthma With Borage and Echium Seed Oils PHASE1/PHASE2COMPLETED
Investigation the Effect of Montelukast in COVID-19 PHASE2UNKNOWN
Treating Exacerbations of Asthma With Oral Montelukast in Children PHASE2COMPLETED
Comparative Effects of Fish Oil Supplementation and a Montelukast on EIB and Airway Inflammation in Asthma PHASE1COMPLETED
A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A PHASE1COMPLETED
MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial) EARLY_PHASE1RECRUITING
Leukotrienes Pathway in Chinese Children With Sleep-disordered Breathing nanUNKNOWN
The Effectiveness of Montelukast on Atopic Dermatitis in Koreans nanCOMPLETED
The Severe Asthma Research Program III-Boston Clinical Site nanCOMPLETED
Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses nanCOMPLETED
A Mechanistic Study to Evaluate the Efficacy of Montelukast on Airway Function in Asthma nanUNKNOWN
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B nanCOMPLETED
Investigation of Lipoxin A4, Annexin A1 and Interleukin-1 Beta Levels in Individuals With Periodontitis. nanCOMPLETED
Ketorolac Irrigant on Post Operative Pain nanUNKNOWN
Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial nanCOMPLETED
Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT nanCOMPLETED
Effect of Montelukast on the Expression and Variation of TGF-β for Children With Mild Persistent Asthma nanCOMPLETED
PGE2/IL-22 Pathway in Various Forms of Eczema nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LTB4R2 binder may also engage these)

ProteinNameSimilarity
Q9JJL9 — 1.000 Q9JJL9 →
Q924U0 — 1.000 Q924U0 →
CCR10 C-C chemokine receptor type 10 0.986 landscape →
LTB4R Leukotriene B4 receptor 1 0.984 landscape →
Q9JL21 — 0.982 Q9JL21 →
Q3T181 — 0.974 Q3T181 →
Q8HYC3 — 0.971 Q8HYC3 →
O00155 — 0.970 O00155 →
UTS2R Urotensin-2 receptor 0.966 landscape →
Q9R0Q2 — 0.963 Q9R0Q2 →
P0C5I1 — 0.962 P0C5I1 →
O88855 — 0.962 O88855 →
Q9BDQ5 — 0.961 Q9BDQ5 →
A0A6I8PUB9 — 0.960 A0A6I8PUB9 →
Q5KSK8 — 0.960 Q5KSK8 →
P48748 — 0.958 P48748 →
GALR3 Galanin receptor type 3 0.957 landscape →
Q76JV1 — 0.956 Q76JV1 →
Q99678 — 0.955 Q99678 →
GPR35 G-protein coupled receptor 35 0.954 landscape →
F2RL3 Proteinase-activated receptor 4 0.953 landscape →
Q8HZN9 — 0.953 Q8HZN9 →
FFAR1 Free fatty acid receptor 1 0.950 landscape →
O88410 — 0.950 O88410 →
CXCR3 C-X-C chemokine receptor type 3 0.949 landscape →
RXFP4 Relaxin-3 receptor 2 0.948 landscape →
Q5MD61 — 0.947 Q5MD61 →
Q867B2 — 0.947 Q867B2 →
Q684M3 — 0.946 Q684M3 →
AVPR2 Vasopressin V2 receptor 0.946 landscape →